Clear Street Downgrades Janux Therapeutics to Hold, Lowers Price Target to $12
Benzinga Newsdesk 9 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold and lowers the price target from $32 to $12.
Clear Street analyst Kaveri Pohlman downgrades Janux Therapeutics (NASDAQ:JANX) from Buy to Hold and lowers the price target from $32 to $12.